Pritoxaximab

Cat

TAB-896

Target

Shiga toxin 1 B subunit

Type

IgG1 - kappa

Immunogen

The details of the immunogen for this antibody are not available.

Species Reactivity

E. coli

Expression Host

CHO

Applications

Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, IHC and most other immunological methods.

CAS

1351470-16-0

Predicted N terminal

QVQLQESG

Molecular Weight

Approximately 150 kDa

Purity

Purity >95% by SDS-PAGE.

Size

1mg

Storage

Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Introduction

Shiga toxins act to inhibit protein synthesis within target cells. The toxin has two subunits designated A and B. The B subunit is a pentamer that binds to specific glycolipids on the host cell, specifically globotriaosylceramide (Gb3).

Antigen Description

Shiga toxins are a family of related toxins with two major groups, Stx1 and Stx2, expressed by genes considered to be part of the genome of lambdoid prophages. The toxin has two subunits—designated A(mol. wt. 32000 D) and B(mol. wt. 7700 D)—and is one of the AB5 toxins. The B subunit is a pentamer that binds to specific glycolipids on the host cell, specifically globotriaosylceramide (Gb3). Following this, the A subunit is internalised and cleaved into two parts. The A1 component then binds to the ribosome, disrupting protein synthesis.

Keywords

Shiga toxin 1 B subunit; Shiga toxins

Download Datasheet:

TAB-006

Anti-Human TNF Therapeutic Antibody (Remicade)

TAB-171

Anti-Human CD4 Therapeutic Antibody

TAB-896

Anti-Shiga toxin 1 B subunit Therapeutic Antibody

TAB-731

Anti-GD2 Therapeutic Antibody

TAB-760

Anti-FCER2/CD32 Therapeutic Antibody

TAB-215

Anti-Human CD80 Therapeutic Antibody

TAB-197

Anti-Human SDC1 Therapeutic Antibody

TAB-003

Anti-Human EGFR Therapeutic Antibody (Erbitux)

TAB-207

Anti-Human CD20 Therapeutic Antibody

TAB-131

Anti-Human GD3 ganglioside Therapeutic Antibody